Renal Manifestations in Juvenile Idiopathic Arthritis (JIA) and the Use of Monoclonal Antibodies for Its Treatment: A Systematic Review
DOI:
https://doi.org/10.56570/jimgs.v2i1.96Keywords:
Juvenile idiopathic arthritis, Renal manifestations, Nephropathy, Nephropathy Nephropathy, TocilizumabAbstract
Juvenile idiopathic arthritis (JIA) is a group of chronic childhood arthropathies in which various joints are affected. Along with the joints being involved, long-standing arthritis can lead to other systemic involvements. Eyes, kidneys, and skin are some examples. It is no surprise that we come across many patients suffering from renal complications due to long-standing JIA. This systematic review aimed to focus on the renal involvement seen in JIA and the use of monoclonal antibodies in its treatment. A systematic review was performed using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and researching studies on databases like PubMed, PubMed Central, and Google Scholar on June 26, 2022. Assessment tools like Cochrane, SANRA, and JBI Tool were used for quality assessment and the selection of articles. Followed by the quality assessment, seven studies were included in the final selection. These were two randomized control trials, four case reports, and one literature review. In conclusion, many cases involving renal complications along with JIA were seen, and Tocilizumab has proved to be efficacious in improving renal complications in JIA. This review encourages further study and research into the topic to understand the effects on JIA and the use of monoclonal antibodies as therapy.References
Zaripova LN, Midgley A, Christmas SE, Beresford MW, Baildam EM, Oldershaw RA. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J. 2021;19(1):135. doi:10.1186/s12969-021-00629-8.
Lin CH, Lin CL, Shen TC, Wei CC. Epidemiology and risk of juvenile idiopathic arthritis among children with allergic diseases: a nationwide population-based study. Pediatr Rheumatol Online J. 2016;14(1):15. doi:10.1186/s12969-016-0074-8.
Huang Z, Lee PY, Yao X, Zheng S, Li T. Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis. Pediatrics. May 2019;143(5):e20182845. doi:10.1542/peds.2018-2845.
Parola C, Neumeier D, Reddy ST. Integrating high-throughput screening and sequencing for monoclonal antibody discovery and engineering. Immunology. 2018;153(1):31-41. doi:10.1111/imm.12838.
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi:10.1136/bmj.d5928.
Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, Stephenson M, Aromataris E. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18(10):2127-2133. doi:10.11124/JBISRIR-D-19-00099.
Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:5. doi:10.1186/s41073-019-0064-8.
Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009, 6:e1000097. 10.1371/journal.pmed.1000097
9 Chantarogh S, Vilaiyuk S, Tim-Aroon T, Worawichawong S. Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: BMC Nephrol. 2017;18(1):159. doi:10.1186/s12882-017-0573-y..
Maleknejad M, Moshari J, Azarfar A, Esmaeili M, Zabolynejad N, Rezayi Yazdi Z, Ghane Sharbaf F. Renal amyloidosis due to juvenile rheumatoid arthritis occurring in early childhood. J Pediatr Nephrol. 2015;3(2):79-81. doi:10.22037/jpn.v3i2.8203.
Kwiatkowska M, Jednacz E, Rutkowska-Sak L. Juvenile idiopathic arthritis complicated by amyloidosis with secondary nephrotic syndrome - effective treatment with tocilizumab. Reumatologia. 2015;53(3):157-160. doi:10.5114/reum.2015.53138.
Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, Schneider R, Berkun Y, Calvo I, Erguven M, Goffin L, Hofer M, Kallinich T, Oliveira SK, Uziel Y, Viola S, et al; PRCSG. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396-2406. doi:10.1056/NEJMoa1205099.
De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P, Wouters C, Xavier R, Zemel L, Baildam E, Burgos-Vargas R, Dolezalova P, Garay SM, Merino R, Joos R, Grom A, et al; PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385-2395. doi:10.1056/NEJMoa1112802.
Huang Z, Lee PY, Yao X, Zheng S, Li T. Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis. Pediatrics. 2019;143(5):e20182845. doi:10.1542/peds.2018-2845.
Marzan KA. Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions. Adolesc Health Med Ther. 2012;3:85-93. doi:10.2147/AHMT.S22607.
